Core Points - NewGenIvf Group Limited is progressing with a reverse merger with European Wellness Investment Holdings Limited, with the signing date for the Share Purchase Agreement extended to February 28, 2025 to allow for due diligence and compliance with NASDAQ requirements [1][2][3] - The reverse merger is valued at approximately US$452 million, with a deemed price of US$3.20 per share, which is expected to enhance market visibility and support the company's continued listing on the NASDAQ [3] - The partnership with EWIHL is aimed at leveraging synergies in the healthcare sector, particularly in regenerative medicine and stem cell therapies, under the leadership of Prof. Dato' Sri Dr. Mike K.S. Chan, who has 39 years of expertise in the field [3] Company Overview - NewGen is a comprehensive fertility services provider in Asia, offering a range of fertility treatments and services, including assisted reproductive technology, egg and sperm donation, and surrogacy [4] - The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, focusing on increasing access to infertility treatment for couples and individuals [4] - European Wellness Investment Holdings Limited is recognized for its advancements in stem cell therapeutics and regenerative medicine, controlling multiple brands and products in the healthcare sector [5][6]
NewGen Progresses Reverse Merger Plans with Engagement of Legal Teams and Updated Timeline